Hsu 2000a.
Methods | Randomised clinical trial, Taiwan | |
Participants | 80 hospitalised adults admitted for colon resection due to colorectal cancer, at nutritional risk due to major surgery Male:Female = 44:36 Mean age = 61.6 years Exclusion criteria: previous gastric resection, previous vagotomy, and active peptic ulcer |
|
Interventions | Experimental group 1: Received enteral nasogastric feeding, started from 500 kcal/day, and if tolerated increased to 1500 kcal/day, as well as Osmolite HN (protein: 4.2 g, fat: 3.5 g, carbohydrate: 13.4 g)/100 kcal (n = 20)
Experimental group 2: Received enteral nasogastric feeding, started from 500 kcal/day, and if tolerated increased to 1500 kcal/day, as well as Pulmocare (protein: 4.2 g, fat: 6.1 g, carbohydrate: 7 g)/100 kcal(n = 20) Experimental group 3: Received enteral nasogastric feeding, started from 500 kcal/day, and if tolerated increased to 1500 kcal/day, as well as AlitraQ (protein: 4.2 g, fat: 2 .1 g, carbohydrate: 18.2 g)/100 kcal. (n = 20) Control group: No oral intake for a week(n = 20) |
|
Outcomes | Change of intragastric pH after surgery and change of intragastric pH after tube‐feeding | |
Study dates | April 1997 to February 1998 | |
Notes | Same trial as Hsu 2000b and Hsu 2000c with the results from experimental group 1 vs control. We contacted the authors on 13th December 2015 by email: tzuchi@ms2.mmh.org.tw. We received no reply. | |
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Unclear risk | Not described |
Allocation concealment (selection bias) | Unclear risk | Not described |
Blinding of participants and personnel (performance bias) All outcomes | Unclear risk | Not described |
Blinding of outcome assessment (detection bias) All outcomes | Unclear risk | Not described |
Incomplete outcome data (attrition bias) All outcomes | Unclear risk | The number of participants with incomplete data was not reported. |
Selective reporting (reporting bias) | Unclear risk | The trial did not properly describe mortality,or serious adverse events. |
For‐profit bias | Unclear risk | It was unclear how the trial was funded. |
Other bias | Low risk | The trial appeared to be free of other components that could put it at risk of bias. |